Daniel Lippis Buys Shares of Edwards Lifesciences Corporation $EW

Key Points

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Daniel Lippis, CVP, TAVR at Edwards Lifesciences Corporation ($EW), bought 619 shares at an average price of $72.68, for a total transaction of $44,988.92. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Edwards Lifesciences Corporation Stock Up 0.3%

Shares of Edwards Lifesciences Corporation ($EW) traded around $90.46 on Wednesday, up 0.3% for the day.

Last price$90.46
Market cap$52.31B
P/E ratio53.70
Forward P/E26.87
PEG ratio2.16
Beta0.85
52-week low$72.30
52-week high$96.29
50-day MA$89.39
200-day MA$84.83
Current ratio4.52
Quick ratio3.45
Debt-to-equity0.07

Edwards Lifesciences Corporation Earnings

EPS (ttm)$1.69
Revenue (ttm)$6.51B
Revenue growth13.60%
Net margin15.43%
Return on equity9.18%
Next earningsOct 29, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$100.96
High target$110
Low target$84
Analysts covering26

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

ExchangeNYSE
SectorHealthcare
IndustryMedical Devices
HeadquartersIrvine, CA
CEOMr. Bernard J. Zovighian
Employees16,000

Get Edwards Lifesciences Corporation alerts

New 13F filings, insider trades, and analyst moves on $EW, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.